(Q35117370)

6 August 2017

1 reference

title

Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors (English)

1 reference

6 August 2017

Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1385/ENDO:20:3:285

28 December 2023

1 reference

https://api.crossref.org/works/10.1385/ENDO:20:3:285

28 December 2023

1

Wouter W de Herder

1 reference

6 August 2017

author name string

Steven W. J. Lamberts

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721509

28 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12721509

28 December 2023

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

http://www.springerlink.com/index/pdf/10.1385/ENDO:20:3:285

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1385/ENDO:20:3:285

28 December 2023

1 reference

6 August 2017

volume

20

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

285-290

1 reference

https://scigraph.springernature.com/pub.10.1385/endo:20:3:285

6 August 2017

exact match

0 references

cites work

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

12 December 2020

Chemoembolization of hepatic neoplasms: safety, complications, and when to worry

1 reference

12 December 2020

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

1 reference

12 December 2020

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

Effects of octreotide on lower esophageal sphincter in patients with cirrhosis and portal hypertension

1 reference

12 December 2020

1 reference

12 December 2020

A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice

1 reference

12 December 2020

[A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide]

1 reference

12 December 2020

Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea

1 reference

12 December 2020

Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours

1 reference

12 December 2020

Established clinical use of octreotide and lanreotide in oncology

1 reference

12 December 2020

Octreotide in the treatment of refractory diarrhea

1 reference

12 December 2020

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

12 December 2020

Somatostatin analogue: use in the treatment of vipoma with hypercalcemia

1 reference

12 December 2020

Localization of Neuroendocrine Tumors Using Somatostatin Receptor Imaging With Indium-111-Pentetreotide (OctreoScan)

1 reference

12 December 2020

Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors

1 reference

12 December 2020

Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety

1 reference

12 December 2020

Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide

1 reference

12 December 2020

Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin

1 reference

12 December 2020

Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide

1 reference

12 December 2020

Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.

1 reference

12 December 2020

1 reference

12 December 2020

The role of somatostatin analogues in the treatment of refractory diarrhoea

1 reference

12 December 2020

Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours

1 reference

12 December 2020

Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome

1 reference

12 December 2020

Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours

1 reference

12 December 2020

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

12 December 2020

OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy

1 reference

12 December 2020

Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.

1 reference

12 December 2020

111In-octreotide scintigraphy in oncology

1 reference

12 December 2020

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide

1 reference

12 December 2020

Treatment of metastasising GRF-producing tumour with a long-acting somatostatin analogue

1 reference

12 December 2020

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

12 December 2020

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma

1 reference

12 December 2020

Palliation of malignant intestinal obstruction using octreotide

1 reference

12 December 2020

Receptor imaging in the diagnosis and treatment of pituitary tumors

1 reference

12 December 2020

Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.

1 reference

12 December 2020

A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome

1 reference

12 December 2020

[Spontaneous regression of liver metastases in neuroendocrine tumors of the abdomen]

1 reference

12 December 2020

[A metastatic neuroendocrine tumor with exceptional outcome!].

1 reference

12 December 2020

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

1 reference

12 December 2020

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

1 reference

12 December 2020

Octreotide therapy in AIDS-related, refractory diarrhea: results of a multicentre Canadian-European study. Octreotide International Multicentre AIDS-Diarrhea Study.

1 reference

12 December 2020

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

12 December 2020

Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery

1 reference

12 December 2020

The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors

1 reference

12 December 2020

Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour

1 reference

12 December 2020

Carcinoid crisis during transesophageal echocardiography

1 reference

12 December 2020

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

12 December 2020

Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers

1 reference

12 December 2020

Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results

1 reference

12 December 2020

[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment

1 reference

12 December 2020

Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy

1 reference

12 December 2020

Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related protein

1 reference

12 December 2020

Therapy of the malignant carcinoid syndrome

1 reference

12 December 2020

Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial

1 reference

12 December 2020

Rapid reversal of carcinoid crisis with a somatostatin analogue

1 reference

12 December 2020

Octreotide in the treatment of refractory diarrhoea and intestinal fistulae

1 reference

12 December 2020

Anesthesia for patients with carcinoid syndrome

1 reference

12 December 2020

Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238

1 reference

12 December 2020

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects

1 reference

12 December 2020

Octapeptide somatostatin-analogue therapy of Cushing's syndrome.

1 reference

12 December 2020

Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy.

1 reference

12 December 2020

1 reference

12 December 2020

Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995

1 reference

12 December 2020

Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration

1 reference

12 December 2020

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

12 December 2020

Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon

1 reference

12 December 2020

Octreotide therapy for tumor-induced osteomalacia

1 reference

12 December 2020

Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management

1 reference

12 December 2020

Peptide receptors in gut endocrine tumours

1 reference

12 December 2020

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs

1 reference

12 December 2020

Octreotide therapy for human immunodeficiency virus--associated diarrhea: pitfalls in drug development

1 reference

12 December 2020

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

1 reference

12 December 2020

Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

Octreotide in the management of treatment-related diarrhoea.

1 reference

12 December 2020

Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema

1 reference

12 December 2020

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

1 reference

12 December 2020

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

12 December 2020

Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea

1 reference

12 December 2020

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

1 reference

12 December 2020

Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues

1 reference

12 December 2020

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

1 reference

12 December 2020

Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver

1 reference

12 December 2020

Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects

1 reference

12 December 2020

Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.

1 reference

12 December 2020

Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction.

1 reference

12 December 2020

1 reference

12 December 2020

Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients

1 reference

12 December 2020

Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.

1 reference

12 December 2020

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

1 reference

12 December 2020

Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue.

1 reference

12 December 2020

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

12 December 2020

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

1 reference

12 December 2020

Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome

1 reference

12 December 2020

In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.

1 reference

12 December 2020

Somatostatin analogs in oncology: a look to the future

1 reference

12 December 2020

Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors

1 reference

12 December 2020

Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238

1 reference

12 December 2020

Regression of metastatic vipoma with somatostatin analogue SMS 201-995

1 reference

12 December 2020

Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport.

1 reference

12 December 2020

Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes

1 reference

12 December 2020

Somatostatin analogue treatment of neuroendocrine tumours

1 reference

12 December 2020

Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion

1 reference

12 December 2020

Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status

1 reference

12 December 2020

Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil

1 reference

12 December 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

1012747277

0 references

1 reference